Bu çeviri hazırlanıyor. Bu süre içinde İngilizce orijinal sürümü gösteriyoruz.
İş dünyası · 12.10.20171 dk okuma
Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment; Draft Guidance for Industry; Availability
Yerel otomatik çeviri · Kaynağın orijinal dili
Özet
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment." The purpose of this draft guidance is to assist sponsors in all phases of antiviral drug development for prophylaxis and treatment of disease caused by respiratory syncytial virus (RSV) infection.
Kaynağın orijinal dili: Federal Register — Food and Drug AdministrationOrijinal duyuruyu açın →